These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11445747)

  • 1. Tissue factor pathway inhibitor activity in severe sepsis.
    Creasey AA; Reinhart K
    Crit Care Med; 2001 Jul; 29(7 Suppl):S126-9. PubMed ID: 11445747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Coagulation inhibitors in severe sepsis: state of the art].
    Fourrier F
    Rev Med Interne; 2003 May; 24(5):295-304. PubMed ID: 12763175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
    Enkhbaatar P; Okajima K; Murakami K; Uchiba M; Okabe H; Okabe K; Yamaguchi Y
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1752-9. PubMed ID: 11069808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis.
    Abraham E
    Crit Care Med; 2000 Sep; 28(9 Suppl):S31-3. PubMed ID: 11007194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of tissue factor and its inhibitor in hemostasis].
    Naumnik B; Małyszko J; Myśliwiec M
    Przegl Lek; 1998; 55(2):68-73. PubMed ID: 9695646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model.
    Elsayed YA; Nakagawa K; Kamikubo YI; Enjyoji KI; Kato H; Sueishi K
    Am J Clin Pathol; 1996 Nov; 106(5):574-83. PubMed ID: 8929465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis.
    Gando S; Kameue T; Morimoto Y; Matsuda N; Hayakawa M; Kemmotsu O
    Crit Care Med; 2002 Aug; 30(8):1729-34. PubMed ID: 12163784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor pathway inhibitor: potential therapeutic applications.
    Bajaj MS; Bajaj SP
    Thromb Haemost; 1997 Jul; 78(1):471-7. PubMed ID: 9198199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor pathway inhibitor and antithrombin trial results.
    LaRosa SP; Opal SM
    Crit Care Clin; 2005 Jul; 21(3):433-48. PubMed ID: 15992666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells.
    Kamikubo Y; Nakahara Y; Takemoto S; Hamuro T; Miyamoto S; Funatsu A
    FEBS Lett; 1997 Apr; 407(1):116-20. PubMed ID: 9141493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
    Lindhout T; Franssen J; Willems G
    Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin.
    Kamikubo Y; Hamuro T; Matsuda J; Shinya N; Miyamoto S; Funatsu A; Kato H
    Thromb Haemost; 1996 Oct; 76(4):621-6. PubMed ID: 8903006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.
    Levi M; de Jonge E; van der Poll T
    Crit Care Med; 2001 Jul; 29(7 Suppl):S90-4. PubMed ID: 11445740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model.
    Rapp JH; Pan XM; Ghermay A; Gazetas P; Brady SE; Reilly LM
    J Vasc Surg; 1997 Apr; 25(4):726-9. PubMed ID: 9129630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TFPI-dependent activities of protein S.
    Peraramelli S; Rosing J; Hackeng TM
    Thromb Res; 2012 May; 129 Suppl 2():S23-6. PubMed ID: 22425215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.
    Al Otair HA; Abdel Gader AG; Khurshid SM; Alzeer AH; Al Momen AK; Al Shaikh M; Al Gahtani F; Al Aseri ZA; Abdelrazik HA
    Turk J Haematol; 2016 Jun; 33(2):112-8. PubMed ID: 26377606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving role of tissue factor and its pathway inhibitor.
    Doshi SN; Marmur JD
    Crit Care Med; 2002 May; 30(5 Suppl):S241-50. PubMed ID: 12004243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor.
    Huang ZF; Wun TC; Broze GJ
    J Biol Chem; 1993 Dec; 268(36):26950-5. PubMed ID: 8262929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.